



## **Pascal Biosciences Settles Certain Outstanding Payables with Issuance of Shares and Details Share-related Compensation to Employees**

**VANCOUVER, BRITISH COLUMBIA**, March 14, 2022- Pascal Biosciences Inc. (“**Pascal**” or the “**Company**”) (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB-FF). Pascal has arranged for the settlement of up to \$474,812 in payables with the issuance of up to 5,935,151 common shares of the Company (“**Shares**”) at a deemed priced at \$0.08 per share.

Additionally, on February 28, 2022, the Company granted an aggregate of 500,000 stock options to the CEO Dr. Brian Bapty pursuant to the Company’s Stock Option Plan. These options are exercisable at a price of \$0.08 per share and will be exercisable for a period of five years, vesting quarterly over one year. All share and option issuances are subject to approval by shareholders at the next AGM. Included in Dr. Bapty’s employment agreement is a provision that his monthly salary of \$15,500 (increasing to \$25,000 with the achievement of certain milestones related to the company’s fiscal well-being) can be paid partly in shares (priced at \$0.10/share during the first year) to provide some flexibility in managing cash flow. In addition to his base salary, a total of \$450,000 in bonuses are payable (in shares and cash) upon the achievement of certain corporate development milestones. These milestones will be disclosed as they are achieved. The issuance of all shares is subject to the acceptance of the TSX.V.

“When I joined Pascal, I was pleased to find passionate, extremely capable scientists dedicated to adding value to the development pipeline,” said Dr. Bapty. “Ensuring capital is available and prioritizing research to programs that can best create value for shareholders is our goal, and we look forward to demonstrating these capabilities in both the short and long term.”

### **ABOUT PASCAL BIOSCIENCES INC.**

Pascal is a biotechnology company targeting innovative therapies for cancer, including targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics. Pascal's leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy.

To learn more, visit: <https://www.pascalbiosciences.com/>.

On Behalf of the Board of Directors  
Brian Bapty, CEO

**Company Contact:**

Dr. Patrick Gray

Email: [pgray@pascalbiosciences.com](mailto:pgray@pascalbiosciences.com)

Phone: (206) 650-6765

**Investors:**

[invest@pascalbiosciences.com](mailto:invest@pascalbiosciences.com)

Tel: 206-221-3443

**Forward-Looking Statements****DISCLAIMER**

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at [www.sedar.com](http://www.sedar.com). Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

**“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”**